A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
Recruiting · Phase 1 · NCT07401862
Conditions: Hepatic Insufficiency
At a glance
- Research payments reported, 2025
- $140,185
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 36
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3841136 (drug)
- Dates
- Started 2026-02-10; completion 2027-03
- Results posted
- Not yet
The main purpose of this study is to evaluate how a medicine, LY3841136, works in participants with different levels of liver damage and in participants with healthy liver. The researchers want to see how the medicine is absorbed and used by the body, and if it causes any side effects, in participants with mild, moderate, or severe liver damage, as well as in participants with normal liver function. For each participant, the study will last about 14 weeks, which will include a stay at the clinical research unit for 5 nights.
From ClinicalTrials.gov, last updated 2026-06-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $140,185 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kimberly Cruz, M.D. Pediatrics · Pompano Beach, FL
- Kathleen M. Doisy, MD Pediatrics · Columbia, MO
- Gene W. Voskuhl, MD Infectious Disease · Sherman, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $46,729
- Covance Clinical Research LP Dallas $46,728
- Fortrea Clinical Research Unit Inc $46,728
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.